BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kolluri A, Ho M. The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer. Front Oncol 2019;9:708. [PMID: 31428581 DOI: 10.3389/fonc.2019.00708] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 15.7] [Reference Citation Analysis]
Number Citing Articles
1 Schepers EJ, Lake C, Glaser K, Bondoc AJ. Inhibition of Glypican-3 Cleavage Results in Reduced Cell Proliferation in a Liver Cancer Cell Line. Journal of Surgical Research 2023;282:118-128. [DOI: 10.1016/j.jss.2022.09.011] [Reference Citation Analysis]
2 Wu T, Song Z, Huang H, Jakos T, Jiang H, Xie Y, Zhu J. Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma. International Immunopharmacology 2022;113:109393. [DOI: 10.1016/j.intimp.2022.109393] [Reference Citation Analysis]
3 Koksal AR, Thevenot P, Aydin Y, Nunez K, Sandow T, Widmer K, Nayak L, Scott J, Delk M, Moehlen MW, Cohen AJ, Dash S. Impaired Autophagy Response in Hepatocellular Carcinomas Enriches Glypican-3 in Exosomes, Not in the Microvesicles. J Hepatocell Carcinoma 2022;9:959-72. [PMID: 36105695 DOI: 10.2147/JHC.S376210] [Reference Citation Analysis]
4 Aljabban J, Rohr M, Syed S, Cohen E, Hashi N, Syed S, Khorfan K, Aljabban H, Borkowski V, Segal M, Mukhtar M, Mohammed M, Boateng E, Nemer M, Panahiazar M, Hadley D, Jalil S, Mumtaz K. Dissecting novel mechanisms of hepatitis B virus related hepatocellular carcinoma using meta-analysis of public data. World J Gastrointest Oncol 2022; 14(9): 1856-1873 [DOI: 10.4251/wjgo.v14.i9.1856] [Reference Citation Analysis]
5 Busato D, Mossenta M, Dal Bo M, Macor P, Toffoli G. The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma. IJMS 2022;23:10279. [DOI: 10.3390/ijms231810279] [Reference Citation Analysis]
6 Wishart TFL, Lovicu FJ. Heparan sulfate proteoglycans (HSPGs) of the ocular lens. Prog Retin Eye Res 2022;:101118. [PMID: 36068128 DOI: 10.1016/j.preteyeres.2022.101118] [Reference Citation Analysis]
7 Fernandes-ferreira R, Tenani GD, Pinhel MADS, Abrantes AMC, Botelho MFRR, Silva RDCMAD, Souza DRS, Silva RFD. GENES EXPRESSION AND SERUM BIOMARKERS FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA, CIRRHOSIS AND HEPATITIS C. Arq Gastroenterol 2022;59:394-401. [DOI: 10.1590/s0004-2803.202203000-71] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Muralidharan S, Kervarrec T, Weiss GJ, Samimi M. Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma. Oncotarget 2022;13:960-7. [DOI: 10.18632/oncotarget.28260] [Reference Citation Analysis]
9 Tian Y, Wang X, Cramer Z, Rhoades J, Estep KN, Ma X, Tzivelekidis SA, Katona BW, Johnson FB, Yu Z, Blanco MA, Lengner C, Li N. APC and P53 mutations synergize to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer.. [DOI: 10.1101/2022.07.26.501557] [Reference Citation Analysis]
10 Sibuh BZ, Gahtori R, Al-Dayan N, Pant K, Far BF, Malik AA, Gupta AK, Sadhu S, Dohare S, Gupta PK. Emerging trends in immunotoxin targeting cancer stem cells. Toxicol In Vitro 2022;83:105417. [PMID: 35718257 DOI: 10.1016/j.tiv.2022.105417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Guang Y. Ligand-modified Nanomaterials for Specific Targeting of Hepatocellular Carcinoma. Journal of Modern Nanotechnology 2022;2. [DOI: 10.53964/jmn.2022004] [Reference Citation Analysis]
12 Al-Noshokaty TM, Mesbah NM, Abo-Elmatty DM, Abulsoud AI, Abdel-Hamed AR. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis. Life Sci 2022;303:120675. [PMID: 35640776 DOI: 10.1016/j.lfs.2022.120675] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Shin WR, Park DY, Kim JH, Lee JP, Thai NQ, Oh IH, Sekhon SS, Choi W, Kim SY, Cho BK, Kim SC, Min J, Ahn JY, Kim YH. Structure based innovative approach to analyze aptaprobe-GPC3 complexes in hepatocellular carcinoma. J Nanobiotechnology 2022;20:204. [PMID: 35477501 DOI: 10.1186/s12951-022-01391-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Fitzgerald G, Turiel G, Gorski T, Soro-arnaiz I, Zhang J, Casartelli NC, Masschelein E, Maffiuletti NA, Sutter R, Leunig M, Farup J, De Bock K. MME+ fibro-adipogenic progenitors are the dominant adipogenic population during fatty infiltration in human skeletal muscle.. [DOI: 10.1101/2022.04.22.489158] [Reference Citation Analysis]
15 Chen T, Sun D, Wang Q, Zhou T, Tan J, Xu C, Cheng H, Shen W. α-Hederin Inhibits the Proliferation of Hepatocellular Carcinoma Cells via Hippo-Yes-Associated Protein Signaling Pathway. Front Oncol 2022;12:839603. [PMID: 35311132 DOI: 10.3389/fonc.2022.839603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zheng X, Liu X, Lei Y, Wang G, Liu M. Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma. Front Oncol 2022;12:824208. [PMID: 35251989 DOI: 10.3389/fonc.2022.824208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
17 Muralidharan S, Kervarrec T, Weiss GJ, Samimi M. Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel Cell Carcinoma.. [DOI: 10.1101/2022.02.06.479301] [Reference Citation Analysis]
18 Váncza L, Karászi K, Péterfia B, Turiák L, Dezső K, Sebestyén A, Reszegi A, Petővári G, Kiss A, Schaff Z, Baghy K, Kovalszky I. SPOCK1 Promotes the Development of Hepatocellular Carcinoma. Front Oncol 2022;12:819883. [DOI: 10.3389/fonc.2022.819883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Li D, Lin S, Hong J, Ho M. Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances. Advances in Cancer Research 2022. [DOI: 10.1016/bs.acr.2022.01.013] [Reference Citation Analysis]
20 Wishart TFL, Lovicu FJ. An Atlas of Heparan Sulfate Proteoglycans in the Postnatal Rat Lens. Invest Ophthalmol Vis Sci 2021;62:5. [PMID: 34730792 DOI: 10.1167/iovs.62.14.5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Pan J, Ho M. Role of glypican-1 in regulating multiple cellular signaling pathways. Am J Physiol Cell Physiol 2021;321:C846-58. [PMID: 34550795 DOI: 10.1152/ajpcell.00290.2021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
22 Mahati S, Fu X, Ma X, Zhang H, Xiao L. Delivery of miR-26a Using an Exosomes-Based Nanosystem Inhibited Proliferation of Hepatocellular Carcinoma. Front Mol Biosci 2021;8:738219. [PMID: 34552961 DOI: 10.3389/fmolb.2021.738219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Bondoc A, Glaser K, Jin K, Lake C, Cairo S, Geller J, Tiao G, Aronow B. Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma. Commun Biol 2021;4:1049. [PMID: 34497364 DOI: 10.1038/s42003-021-02562-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
24 Xue T, Zhao X, Zhao K, Lu Y, Yao J, Ji X. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. Curr Probl Cancer 2021;:100791. [PMID: 34538649 DOI: 10.1016/j.currproblcancer.2021.100791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Zhuo J, Lu D, Wang J, Lian Z, Zhang J, Li H, Cen B, Wei X, Wei Q, Xie H, Xu X. Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. Chin J Cancer Res 2021;33:470-9. [PMID: 34584372 DOI: 10.21147/j.issn.1000-9604.2021.04.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Natarajan A, Zhang H, Ye W, Huttad L, Tan M, Chua MS, Gambhir SS, So SK. A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts. Cancers (Basel) 2021;13:3977. [PMID: 34439132 DOI: 10.3390/cancers13163977] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
27 Yonet-Tanyeri N, Ahlmark BZ, Little SR. Advances in Multiplexed Paper-Based Analytical Devices for Cancer Diagnosis: A Review of Technological Developments. Adv Mater Technol 2021;6:2001138. [PMID: 34447879 DOI: 10.1002/admt.202001138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Schobert IT, Savic LJ. Current Trends in Non-Invasive Imaging of Interactions in the Liver Tumor Microenvironment Mediated by Tumor Metabolism. Cancers (Basel) 2021;13:3645. [PMID: 34359547 DOI: 10.3390/cancers13153645] [Reference Citation Analysis]
29 Yao HP, Zhao H, Hudson R, Tong XM, Wang MH. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov Today 2021;26:1857-74. [PMID: 34224904 DOI: 10.1016/j.drudis.2021.06.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
30 Li N, Spetz MR, Li D, Ho M. Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. Pharmacol Ther 2021;223:107892. [PMID: 33992682 DOI: 10.1016/j.pharmthera.2021.107892] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Bell M, Turkbey EB, Escorcia FE. Radiomics, Radiogenomics, and Next-Generation Molecular Imaging to Augment Diagnosis of Hepatocellular Carcinoma. Cancer J. 2020;26:108-115. [PMID: 32205534 DOI: 10.1097/ppo.0000000000000435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
32 Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia M, Li N, Lu P, Sun B, Ho M, Jia S, Ding T, Gao W. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. J Immunother Cancer 2021;9:e001875. [PMID: 33833049 DOI: 10.1136/jitc-2020-001875] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
33 Hiebert LM. Heparan Sulfate Proteoglycans in Diabetes. Semin Thromb Hemost 2021;47:261-73. [PMID: 33794551 DOI: 10.1055/s-0041-1724118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Lee NH, Kim SJ, Hyun J. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer. Biomedicines 2021;9:347. [PMID: 33808155 DOI: 10.3390/biomedicines9040347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
35 Rodakowska E, Walczak-Drzewiecka A, Borowiec M, Gorzkiewicz M, Grzesik J, Ratajewski M, Rozanski M, Dastych J, Ginalski K, Rychlewski L. Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells. Oncol Lett 2021;21:222. [PMID: 33613711 DOI: 10.3892/ol.2021.12483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Meng P, Zhang YF, Zhang W, Chen X, Xu T, Hu S, Liang X, Feng M, Yang X, Ho M. Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells. Sci Rep 2021;11:40. [PMID: 33420124 DOI: 10.1038/s41598-020-79524-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
37 Shen J, Cai W, Ma Y, Xu R, Huo Z, Song L, Qiu X, Zhang Y, Li A, Cao W, Zhou S, Tang X. hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway.Nanoscale Res Lett. 2020;15:220. [PMID: 33242103 DOI: 10.1186/s11671-020-03451-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
38 Braeuning A, Pavek P. β-catenin signaling, the constitutive androstane receptor and their mutual interactions. Arch Toxicol 2020;94:3983-91. [PMID: 33097968 DOI: 10.1007/s00204-020-02935-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
39 Sherif IO, Al-Mutabagani LA, Sabry D, Elsherbiny NM. Antineoplastic Activity of Chrysin against Human Hepatocellular Carcinoma: New Insight on GPC3/SULF2 Axis and lncRNA-AF085935 Expression. Int J Mol Sci 2020;21:E7642. [PMID: 33076548 DOI: 10.3390/ijms21207642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
40 Ahrens TD, Bang-Christensen SR, Jørgensen AM, Løppke C, Spliid CB, Sand NT, Clausen TM, Salanti A, Agerbæk MØ. The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis. Front Cell Dev Biol 2020;8:749. [PMID: 32984308 DOI: 10.3389/fcell.2020.00749] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
41 Lanzi C, Cassinelli G. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities. Biochemical Pharmacology 2020;178:114084. [DOI: 10.1016/j.bcp.2020.114084] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
42 Fleming BD, Ho M. Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. Biomolecules 2020;10:E934. [PMID: 32575752 DOI: 10.3390/biom10060934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
43 Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart JB, Monboisse JC. Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression. Front Oncol 2020;10:397. [PMID: 32351878 DOI: 10.3389/fonc.2020.00397] [Cited by in Crossref: 85] [Cited by in F6Publishing: 95] [Article Influence: 42.5] [Reference Citation Analysis]
44 Shizu R, Yoshinari K. Nuclear receptor CAR-mediated liver cancer and its species differences. Expert Opin Drug Metab Toxicol 2020;16:343-51. [PMID: 32202166 DOI: 10.1080/17425255.2020.1746268] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
45 Ashrafizadeh M, Rafiei H, Mohammadinejad R, Farkhondeh T, Samarghandian S. Wnt-regulating microRNAs role in gastric cancer malignancy. Life Sci 2020;250:117547. [PMID: 32173311 DOI: 10.1016/j.lfs.2020.117547] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
46 Mansouri V, Razzaghi M, Nikzamir A, Ahmadzadeh A, Iranshahi M, Haghazali M, Hamdieh M. Assessment of liver cancer biomarkers. Gastroenterol Hepatol Bed Bench 2020;13:S29-39. [PMID: 33585001] [Reference Citation Analysis]
47 Chen C, Yang Z, Huang ZS. Progress in research on association between cell signal transduction pathways and hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2019; 27(21): 1330-1338 [DOI: 10.11569/wcjd.v27.i21.1330] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]